Chudenko (1941) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
9 Mar, 2026Executive summary
Achieved record highs in net sales and profit attributable to owners of parent for FY2024, surpassing initial targets despite high raw material and labor costs.
Net sales rose 10.4% year-over-year to ¥221,885 million for the fiscal year ended March 31, 2025.
Strengthened business foundation in the Chugoku region and expanded in urban areas, with notable growth in orders and net sales.
Formed a business alliance with IAQ in Malaysia and received multiple certifications for health and diversity initiatives.
Comprehensive income reached ¥22,075 million, up 16.2% year-over-year.
Financial highlights
FY2024 consolidated net sales rose to ¥221.8 billion, up ¥20.8 billion year-over-year (110%).
Operating profit increased by ¥9.7 billion to ¥21.6 billion (182% YoY); ordinary profit up ¥10.6 billion to ¥23.4 billion (184% YoY).
Gross profit increased from ¥28,529 million to ¥38,928 million year-over-year.
Balance sheet: total assets grew to ¥293.9 billion, equity ratio improved to 77.1%.
Cash and cash equivalents at year-end were ¥34,435 million, up from ¥29,845 million.
Outlook and guidance
FY2025 consolidated net sales forecasted at ¥230.0 billion (+¥8.1 billion YoY), operating profit at ¥22.0 billion (+¥0.3 billion YoY).
Profit attributable to owners of parent expected to decrease to ¥15.8 billion due to absence of prior year’s tax benefit.
Medium-Term Management Plan 2027 targets FY2027 net sales of ¥240.0 billion, operating profit of ¥23.0 billion, and ROE of 7.0% or higher.
Basic earnings per share forecast is ¥291.82.
Latest events from Chudenko
- Record profit growth and raised full-year outlook, with higher interim dividend declared.1941
Q2 20259 Mar 2026 - Record interim profits, higher dividends, and an upward outlook despite lower sales.1941
Q2 20269 Mar 2026 - Strong sales growth and profit recovery, with higher dividends forecast for the year.1941
Q1 20259 Mar 2026 - Strong year-over-year profit and sales growth with an optimistic full-year outlook.1941
Q3 20259 Mar 2026 - Operating profit jumped 49.6% despite a 2.7% drop in net sales year-over-year.1941
Q1 20269 Mar 2026 - Operating profit rose 18.7% despite a 2.5% sales decline; net profit fell 18.2% year-over-year.1941
Q3 20269 Mar 2026